Has Halle Berry confirmed she uses HRT?

Yes. Berry has publicly discussed her use of hormone therapy for menopause across multiple interviews and during her 2024 testimony before the U.S. Congress. She has not disclosed the specific type, dose, or duration of her regimen.

What happens if you stop HRT suddenly?

Hot flashes and night sweats return in roughly half of women. Bone density begins declining within months as estrogen's protective effect on bone resorption is removed. Genitourinary symptoms such as vaginal dryness typically recur as well.

Is there a maximum safe duration for HRT?

Current guidelines from The Menopause Society and the Endocrine Society do not impose a fixed duration limit. They recommend periodic reassessment of symptoms and risks rather than automatic discontinuation at a set time point.

Is tapering HRT better than stopping all at once?

Randomized evidence comparing the two approaches is limited. Clinical trials show similar rates of symptom rebound with both methods. Many clinicians still recommend tapering based on clinical judgment and patient comfort.

Does HRT cause breast cancer?

Combined estrogen-progestogen therapy is associated with a small increase in breast cancer risk with prolonged use (approximately 8 additional cases per 10,000 women-years in the WHI). Estrogen-only therapy has not shown increased risk and may be associated with a slight decrease.

Halle Berry, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Celebrity: Halle Berry
Drug family: Women's HRT (menopausal hormone therapy)
Status: Publicly confirmed user and advocate
Page focus: Long-term maintenance, discontinuation risks, and clinical decision-making
Key clinical takeaway: Abrupt HRT cessation frequently triggers symptom rebound; tapering and individualized risk assessment are supported by current guidelines

Halle Berry's Public Record on HRT

Halle Berry has spoken openly about entering menopause and choosing hormone therapy. In a 2022 interview, she described being misdiagnosed initially and later discovering she was in perimenopause at a younger age than expected. She has discussed her experience publicly and used her platform to push for greater awareness of menopausal health.

Berry founded Respin, a wellness brand with a stated mission of centering menopause in the broader health conversation. She has repeatedly called for reduced stigma around menopause and more equitable access to hormone therapy, including during her testimony before the U.S. Congress in June 2024, where she urged federal investment in menopause research and care.

Her public advocacy is confirmed. The specific formulation, dosage, or duration of her personal HRT regimen has not been disclosed in detail.

What Is Menopausal Hormone Therapy?

Menopausal hormone therapy (MHT), commonly called HRT, replaces estrogen (and, in women with an intact uterus, progesterone) to manage vasomotor symptoms like hot flashes and night sweats, as well as genitourinary syndrome of menopause (GSM), mood disruptions, and accelerated bone loss.

The 2022 Hormone Therapy Position Statement from The Menopause Society (formerly NAMS) affirms that for symptomatic women under 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks. Estrogen therapy remains the most effective treatment for vasomotor symptoms, reducing hot flash frequency by roughly 75% compared to placebo.

The Maintenance Question: How Long Should HRT Continue?

This is the question Berry's advocacy implicitly raises, and it has no single correct answer. Clinical guidelines have shifted substantially since the early 2000s, when the Women's Health Initiative (WHI) results prompted widespread, often premature discontinuation of HRT.

Current guidance from The Menopause Society and the Endocrine Society does not set a fixed duration limit. Instead, both organizations recommend periodic reassessment, weighing ongoing symptom burden against individualized cardiovascular and breast cancer risk profiles.

For bone protection specifically, estrogen's benefits persist only as long as treatment continues. A meta-analysis published in The Lancet demonstrated that bone mineral density gains reverse within two to three years of stopping HRT.

The HealthRX Medical Team's take: The old "use the lowest dose for the shortest time" mantra, born from the initial WHI panic, has been replaced by something more measured. Duration should be driven by the patient's symptom profile, risk factors, and quality-of-life assessment, not by an arbitrary clock. Berry's public stance aligns with what evidence-based menopause specialists now recommend: individualized, ongoing care rather than a one-size-fits-all cutoff.

What Happens When You Stop HRT?

Discontinuation is where many women are caught off guard. The clinical literature identifies several well-documented consequences.

Vasomotor Symptom Rebound

Hot flashes and night sweats frequently return after HRT cessation. A study in JAMA Internal Medicine found that vasomotor symptoms recurred in approximately 50% of women who discontinued HRT, regardless of whether they stopped abruptly or tapered gradually. Women who had more severe symptoms before starting therapy were more likely to experience rebound.

The recurrence rate challenges the assumption that menopause symptoms simply "time out." Some women experience vasomotor symptoms for a decade or longer after their final menstrual period.

Accelerated Bone Loss

Estrogen suppresses osteoclast-mediated bone resorption. When exogenous estrogen is withdrawn, resorption accelerates rapidly. Data from the WHI follow-up showed that fracture protection conferred by HRT disappeared within three to five years of stopping. Women with pre-existing osteopenia face an elevated fracture risk during this post-cessation window.

The FDA and clinical guidelines recommend that women stopping long-term HRT for bone health discuss transition to a bisphosphonate or other antiresorptive agent with their physician.

Genitourinary Symptoms

Vaginal atrophy and urinary symptoms tied to GSM tend to return promptly after systemic HRT discontinuation. Low-dose vaginal estrogen, which carries minimal systemic absorption and a favorable safety profile per the Endocrine Society, can be continued independently of systemic therapy.

Cardiovascular Considerations

The relationship between HRT and cardiovascular risk is timing-dependent. The "timing hypothesis," supported by WHI subgroup analyses and the ELITE trial, suggests that estrogen initiated near menopause onset may be cardioprotective, while initiation after age 60 or more than 10 years post-menopause may increase risk. Discontinuation removes whatever cardiovascular benefit early-initiation therapy may have been providing.

Tapering vs. Abrupt Cessation

There is limited high-quality evidence comparing gradual taper to abrupt cessation. The JAMA Internal Medicine study mentioned above found symptom rebound rates were similar in both groups. Some clinicians still prefer a gradual taper (reducing dose over three to six months) based on clinical experience and patient preference, even though randomized data supporting this approach remain thin.

The HealthRX Medical Team's take: Tapering makes physiological sense and many patients report a smoother transition, but we should be honest that the evidence base is weak. What matters more than the method of stopping is whether the decision to stop is clinically justified and whether alternative therapies are in place for bone health, GSM, and cardiovascular monitoring.

Long-Term Use: What the Evidence Actually Shows

For women considering extended HRT (beyond five to ten years), the risk calculus centers on breast cancer, venous thromboembolism (VTE), and stroke.

Breast cancer: Combined estrogen-progestogen therapy is associated with a modest increase in breast cancer risk with prolonged use. The WHI data showed approximately 8 additional breast cancer cases per 10,000 women-years with combined therapy. Estrogen-only therapy (for women without a uterus) showed no increased breast cancer risk in the WHI and may even be associated with a slight decrease, a finding that persisted through 18 years of follow-up.

VTE and stroke: Oral estrogen increases VTE risk roughly twofold. Transdermal estradiol, which avoids hepatic first-pass metabolism, does not appear to increase VTE risk and is now the preferred route for women with thrombotic risk factors.

The HealthRX Medical Team's take: Long-term HRT is not inherently dangerous, but it is not risk-free. The decision to continue should be re-evaluated annually. Route of administration matters: transdermal estradiol with micronized progesterone represents the regimen most favorably supported by current safety data for extended use.

Where Berry's Advocacy Meets the Evidence

Berry has not publicly disclosed whether she plans to continue HRT indefinitely or has discussed discontinuation with her medical team. What she has done is something with measurable public health value: she has normalized the conversation.

A 2023 survey by the Menopause Society found that nearly 75% of women with menopausal symptoms were not receiving treatment. Stigma, lack of provider education, and lingering fear from the initial WHI coverage all contribute.

Berry's willingness to discuss her own HRT use and to advocate before Congress addresses exactly the access and awareness gaps that clinical organizations have been warning about for years.

Clinical Bottom Line

Stopping HRT is not a simple off-switch. It carries real physiological consequences that should be anticipated, managed, and monitored. Continuing HRT long-term is a legitimate clinical option when the benefit-risk ratio supports it, and that ratio should be evaluated on an individual basis, not by population-level rules of thumb.

Whether Berry continues HRT for life or eventually transitions off it, her public record has already contributed to a shift in how menopausal care is discussed. The clinical literature supports her core message: menopause treatment deserves the same evidence-based, patient-centered rigor as any other chronic health condition.

Frequently asked questions

›